Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Label Revisions Ordered for Somatropin, IFNβ-1a/1b Preparations
April 5, 2022
- SCARDA to Create “Safe and Secure Vaccines” as Command Tower: Chief
April 5, 2022
- Novavax’s COVID-19 Vaccine Up for PAFSC Review on Regular Pathway
April 5, 2022
- MHLW Presents Policy for Use of “Specified Clinical Research” Data in Regulatory Submissions
April 4, 2022
- Ex-JST Chief Michinari Hamaguchi Takes Helm of SCARDA
April 4, 2022
- Japan PM Touts Proposed Emergency Approval Scheme as Bill Enters Diet Deliberations
April 1, 2022
- Fourth COVID Shots for Older Adults and High-Risk People: LDP Project Team
April 1, 2022
- 3 Wholesalers Ordered to Pay 420 Million Yen in Surcharge over Bid-Rigging; JCHO to Suspend Mediceo Too
March 31, 2022
- Working Group Launched under Pharma Industry Vision Meets for 1st Time
March 31, 2022
- Vonvendi Label Revised for Routine Prophylaxis in VWD
March 30, 2022
- Vaccine Chief Horiuchi to Bow Out at March-End
March 30, 2022
- PMD Law Amendment Bill to Enter Diet Debate March 31, CDP’s Counter-Legislation Too
March 30, 2022
- Japan Grants Orphan Status to Tafinlar, Mekinist, and 4 More APIs
March 30, 2022
- Japan Approves Kerendia, Vabysmo, Ondexxya, Takhzyro and More
March 29, 2022
- Govt’s Avigan Purchase Was a Result of Pursuing Possible Scenarios: PM
March 29, 2022
- Legal Initiatives Necessary to Ensure Stable Drug Supplies: MHLW Official
March 28, 2022
- MHLW Urges Prefectural Govts to Prep for 4th COVID Shot over Next 2 Months
March 28, 2022
- MHLW to Work Out Physician Payment Disclosure Method with Drug Makers towards Amendment of Clinical Research Law
March 28, 2022
- MHLW Panel OKs 84 More Health Damage Claims for COVID-19 Vaccines
March 28, 2022
- Japan Govt OKs 1.3 Trillion Yen Reserve Fund Use for COVID Measures
March 28, 2022
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…